prev next front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |33 |34 |35 |36 |37 |38 |39 |40 |41 |42 |43 |44 |45 |46 |47 |48 |49 |50 |51 |review

Key Point: In the STELLAR trial, the 10-mg dose of rosuvastatin lowered LDL-C
more effectively than atorvastatin 10 mg and the 10-mg to 40-mg doses of simvastatin
and pravastatin.

This slide shows data from the STELLAR trial comparing rosuvastatin, atorvastatin, simvastatin and pravastatin across their respective dose ranges

Rosuvastatin 10 mg resulted in a statistically significant greater percentage reduction in LDL-C compared with atorvastatin 10 mg; simvastatin 10 mg, 20 mg, or 40 mg; and pravastatin 10 mg, 20 mg, or 40 mg (P<.002)

In a comparison of dose-response curves, rosuvastatin 10 mg to 40 mg reduced LDL-C significantly more than atorvastatin 10 mg to 80 mg (4.1%; P<.001)




 

Reference

Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin
versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial).
Am J Cardiol. 2003;93:152-160.